ReviewJournal of diabetes and metabolic disorders2025
Safety, efficacy and psychological impact of Omnipod hybrid closed loop system in children, adolescents, and adults in 24 h and nighttime: Systematic review with additional meta-analysis.
Review in Journal of diabetes and metabolic disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Automated insulin delivery has been developed with various algorithms and designs. Omnipod 5 is the latest Commercially available device. We aimed to explore the safety efficacy and psychological impact of the new Omnipod hybrid closed-loop system. Methods: We used PubMed, Google Scholar, Scopus, Web of Science, and Cochrane Library for our search, we analyzed pre and post-data for continuous glucose monitoring data and HbA1C using RevMan software. When we observed heterogeneity, we used random effect model otherwise fixed effect model was used. We addressed heterogeneity using leave-one-out sensitivity analysis. We performed subgroup analysis based on study design and age subgroups. We reported outcomes that couldn't be analyzed narratively. Results: Out of 12 studies with 13 reports, we analyzed pre and post-data of eight studies. Pooled data of 665 patients showed significant improvement in time in range 70-180mg/dl [MD 11.30% [95% CI: 9.75 to 12.84], P < 0.00001]. Time above range 180mg/dl was significantly improved [MD -9.88% [95% CI: -11.52 to -8.25], P < 0.00001]. Among six trials nighttime time below range 70mg/dl showed significant results TBR [MD -2.6% [95%CI: -3.77 to -1.44], p < 0.0001] with Considerable heterogeneity that was fixed by sensitivity analysis. Omnpod hybrid closed loop [HCL] showed improvement in type 1 diabetes distress score which is consistent among reported studies. Conclusion: Post Omnipod HCL usage showed improvement in 24h and nighttime which needs confirmation with more evidence. Supplementary Information: The online version contains supplementary material available at 10.1007/s40200-025-01639-z.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.